A Cdc2/Cdk1 inhibitor, purvalanol A, has been shown to enhance the cytotoxic effects of taxol by Op18/stathmin in in-vitro NSCLC [62]. This evidence concerns the gene CDK1 and non-small cell lung carcinoma.